BDNF raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
== Occurrence == Many inorganic compounds are found in nature as minerals. Soil may contain iron sulfide as pyrite or calcium sulfate as gypsum. Inorganic compounds are also found multitasking as biomolecules: as electrolytes (sodium chloride), in energy storage (ATP) or in construction (the polyphosphate backbone in DNA).
== O == George Andrew Olah (1927–2017), Hungarian and American chemist who worked on the generation and reactivity of carbocations via superacids; 1994 Nobel Prize in Chemistry Marilyn Olmstead (1943–2020), American chemist, expert in small-molecule crystallography Fred Olsen (1891–1986), British-born American chemist, inventor of the ball propellant manufacturing process Lars Onsager (1903–1976), Norwegian and American physical chemist and theoretical physicist who corrected the Debye-Hückel theory of electrolytic solutions, 1968 Nobel Prize in Chemistry Tony Orchard (1941–2005), British inorganic chemist whose research helped to lay the foundations of much modern consumer electronic technology Joan Oró (1923–2004), Spanish (Catalan) biochemist known for studies of the origin of life Hans Christian Ørsted (1777–1851), Danish chemist and physicist who discovered that electric currents create magnetic fields Wilhelm Ostwald (1853–1932), Baltic German physical chemist, 1909 Nobel Prize in Chemistry for contributions to the fields of catalysis, chemical equilibria and reaction velocities Larry E. Overman (born 1943), American organic chemist developing chemical reactions, particularly transition metal catalyzed reactions Geoffrey Ozin (DPhil 1967), British materials chemist known for research on nanomaterials
=== Structure === The plantar fascia is made up of predominantly longitudinally oriented collagen fibers. There are three distinct structural components: the medial component, the central component (plantar aponeurosis), and the lateral component (see diagram at right). The central component is the largest and most prominent.
Gonzalez became the executive chairman. In August 2024, AbbVie acquired neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an attempt to expand its drug pipeline. In September 2024, AbbVie filed a lawsuit against BeiGene accusing it of stealing trade secrets to develop a competing therapy to treat blood and bone marrow cancers related to the growth of "B cells" after BeiGene hired a former longtime senior AbbVie scientist. In October 2024, AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline. In January 2025, AbbVie acquired Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune area, for $200 million. In the same month, AbbVie announced a $1.64 billion partnership with Neomorph to develop new molecular glue degraders for multiple targets across oncology and immunology, as well as a $1 billion partnership with Simcere Zaiming to develop an investigational drug candidate for multiple myeloma. In May 2025, AbbVie entered into a collaboration and license option deal with ADARx Pharmaceuticals to develop a new type of RNA technology for disease areas like neuroscience, immunology, and oncology. In August 2025, AbbVie acquired Bretisilocin, which is under development for the treatment of major depressive disorder, from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion. In January 2026, AbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over the next 10 years and lower Medicaid prices.
Sources: en.wikipedia.org
=== Kissinger's May 1972 Paris meeting with Tho === On 6 May 1972, Kissinger returned to Paris to face Tho again. Nixon had ordered Kissinger to be severe, saying, "No nonsense. No niceness. No accommodations". As a result, Kissinger was unusually unfriendly, and snapped when Tho mentioned that Senator J. William Fulbright was criticizing the Vietnam War: "Our domestic discussions are no concerns of yours". Tho told Kissinger: "I'm giving an example to prove that Americans share our views", and then stated that the United States had never followed the Geneva Accords. Tho charged that the American terms calling for a withdrawal from Vietnam months after a peace agreement was signed was unacceptable. Kissinger promised that once a peace agreement was signed, a general election would be called to elect a new South Vietnamese president, Thieu would resign, and that the Communists could take in the election. When Kissinger asked when Thieu should resign, Thuy told him, "Tomorrow is best". Kissinger replied: "All other members, except Thieu can remain in the administration, can't they?" Thuy stated that they could, but there had to be release of political prisoners and freedom of the press, leading Kissinger to ask: "Can anybody publish a newspaper in North Vietnam? I ask for my own education". On 19 July 1972, Kissinger again met Tho in Paris.
=== Salt balance === Dermal macrophages facilitate skin homeostasis by regulating the skin's salt composition. For instance, an increase in salt concentration after a salt-heavy meal attracts dermal macrophages that express TonEBP, a transcriptional factor responding to osmotic pressure changes. This process triggers VEGF-C transcription, resulting in the growth of lymph capillaries and blood vessels dilation, regulating salt-sensitive hypertension by lowering the blood pressure. An increase in sodium ions concentration also facilitates the polymerisation of glycosaminoglycans, which helps the storage of sodium ions in the skin. A salt solution such as sodium chloride in the skin can trigger hypertonic stress, which acts as a stimulus for attracting macrophages. A higher salt concentration also causes macrophages activation. It induces the expression of pro-inflammatory genes such as CXCL-1, CCL2, and IL-1 and inhibits anti-inflammatory genes such as CCL18 and CCL22. Hence, the activation of dermal macrophages can be achieved by the local salt concentration, independent of the salt ingested. The expression of such genes could contribute to the skin's defence against parasitic infections.
Foodborne illness (also known as foodborne disease and food poisoning) is any illness resulting from the contamination of food by pathogenic bacteria, viruses, or parasites, as well as prions (the agents of mad cow disease), and toxins such as aflatoxins in peanuts, poisonous mushrooms, and various species of beans that have not been boiled for at least 10 minutes. While contaminants directly cause some symptoms, many effects of foodborne illness result from the body's immune response to these agents, which can vary significantly between individuals and populations based on prior exposure. Symptoms vary depending on the cause. They often include vomiting, fever, aches, and diarrhea and dehydration. Bouts of vomiting can be repeated with an extended delay in between. This is because even if infected food was eliminated from the stomach in the first bout, microbes, like bacteria (if applicable), can pass through the stomach into the intestine and begin to multiply. Some types of microbes stay in the intestine. For contaminants requiring an incubation period, symptoms may not manifest for hours to days, depending on the cause and on the quantity of consumption. Longer incubation periods tend to cause those affected to not associate the symptoms with the item consumed, so they may misattribute the symptoms to gastroenteritis, for example. In low- and middle-income countries in 2010, foodborne disease were responsible for approximately 600 million illnesses and 420,000 deaths, along with an economic loss estimated at US$110 billion annually.
Sources: en.wikipedia.org
Rieske proteins are iron–sulfur protein (ISP) components of cytochrome bc1 complexes and cytochrome b6f complexes and are responsible for electron transfer in some biological systems. John S. Rieske and co-workers first discovered the protein and in 1964 isolated an acetylated form of the bovine mitochondrial protein. In 1979, Trumpower's team isolated the "oxidation factor" from bovine mitochondria and showed it was a reconstitutively-active form of the Rieske iron-sulfur protein. It is a unique [2Fe-2S] cluster in that one of the two Fe atoms is coordinated by two histidine residues rather than two cysteine residues. They have since been found in plants, animals, and bacteria with widely ranging electron reduction potentials from -150 to +400 mV.
9-Carboxymethoxymethylguanine (CMMG) is a compound which is known as the principal metabolite of the antiviral medication aciclovir (and its prodrug valaciclovir), and has been suggested as the causative agent in the neuropsychiatric side effects sometimes associated with these medications. These are mainly suffered by patients with kidney failure or otherwise decreased kidney function, and can include psychotic reactions, hallucinations, and rarely more complex disorders such as Cotard delusion. Patients suffering these symptoms following aciclovir treatment were found to have much higher levels of CMMG than normal, and since this is the first time Cotard delusion has been linked to a drug as a side effect, this discovery may be useful in the study of Cotard delusion and its treatment.
Roseanne Park. Musician/Performer. For services to the United Kingdom COP 26 Presidency and advocacy for the 2021 United Nations Climate Change Conference of the Parties. Gina Cecile Petrie. Director, Department of Environment, Cayman Islands. For services to the Environment and to the community in the Cayman Islands. Richard Anthony Power. Orthopaedic Surgeon, University Hospitals of Leicester NHS Trust; Chair, Health Action Leicester in Ethiopia. For services to Health in Gondar, Northern Ethiopia. Natalie Ray Pray. Former President, the St George's Society, New York, United States of America. For services to UK/US Cultural Relations and to Philanthropy. Phillip Christopher Robinson. Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. James Andrew Rogers. Head of Coordination, Windsor Framework Taskforce, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Lynette Silver. Historian and Author. For services to British Families of World War II personnel. Claire Sonia van Straubenzee. Founder and Trustee, The Henry van Straubenzee Memorial Fund. For services to Children's Education in Uganda. Edward Robert Syfret. Angola Programme Manager, the HALO Trust. For services to Humanitarian Demining in Angola. Margery Anne Taylor. District Treasurer and District Training Officer, Royal British Legion, Spain South. For services to Veterans in Spain. Jacqueline Barbara Teasdale (Tig James). Co-President, British in Portugal. For services to the British Community in Portugal. John Robert Thurlow.
== Molecular characteristics == PDRN is a polyanionic, hydrophilic molecule whose molecular weight varies due to differences in biological extraction and purification processes. Even though this molecule ranges from 50 to 1500 kDa (primarily between 80 - 200 kDa), lower-molecular-weight fragments have shown better biological activity compared to higher-molecular-weight counterparts. Salmon-derived PDRN fragment characteristics have become the standard because of its ready availability and ease of processing, yields highly purified product (~95%) helping avoid potential immunological side effects.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.